Profile data is unavailable for this security.
About the company
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals and related services. Its product portfolio is spread over seven therapeutic/product areas encompassing Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals & Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, and others.
- Revenue in INR (TTM)278.95bn
- Net income in INR27.70bn
- Incorporated1986
- Employees15.69k
- LocationAurobindo Pharma LtdWater Mark Building,, Plot No. 11Survey no.9, Kondapur, Hitech CityHyderabad,TelanganaHYDERABAD 500032IndiaIND
- Phone+91 4 066725000
- Fax+91 4 023741080
- Websitehttps://www.aurobindo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPCA Laboratories Ltd | 71.86bn | 5.64bn | 339.58bn | 16.17k | 60.17 | -- | 36.28 | 4.73 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
| GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 360.61bn | 3.68k | 68.16 | -- | 60.34 | 10.89 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
| Biocon Ltd | 146.13bn | 12.00bn | 366.70bn | 3.41k | 30.55 | -- | 12.16 | 2.51 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 587.11bn | 16.87k | 37.32 | -- | 31.42 | 4.65 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 662.87bn | 15.69k | 23.95 | -- | 15.49 | 2.38 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 194.80bn | 17.91bn | 736.47bn | 18.97k | 41.24 | -- | 26.18 | 3.78 | 39.19 | 39.19 | 426.18 | -- | -- | -- | -- | 10,268,360.00 | -- | 0.2337 | -- | 0.3443 | 64.99 | 58.56 | 9.29 | 0.3673 | -- | 6.89 | -- | 470.26 | 1.44 | 1.04 | 128.15 | 11.35 | -0.7025 | -4.36 |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 910.76bn | 13.57k | 60.55 | -- | 39.61 | 8.70 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 948.99bn | 18.47k | 54.99 | -- | 44.41 | 9.54 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Zydus Lifesciences Ltd | 186.81bn | 29.56bn | 953.31bn | 23.03k | 32.44 | -- | 25.82 | 5.10 | 29.21 | 29.38 | 184.58 | -- | -- | -- | -- | 8,113,133.00 | -- | 7.92 | -- | 12.61 | 66.21 | 60.14 | 15.81 | 12.89 | -- | -- | -- | 20.55 | 14.08 | 7.59 | -12.34 | 1.83 | -0.3532 | 11.38 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 32.52m | 5.55% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 22.15m | 3.78% |
| ICICI Prudential Asset Management Co. Ltd.as of 15 Apr 2024 | 21.98m | 3.75% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Mar 2024 | 16.67m | 2.84% |
| quant Money Managers Ltd.as of 31 Mar 2024 | 14.91m | 2.54% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 10.35m | 1.77% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 6.54m | 1.12% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 5.23m | 0.89% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 4.30m | 0.73% |
| Pzena Investment Management LLCas of 31 Jan 2024 | 3.71m | 0.63% |
